Maikel Wijsbek’s Post

In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:

In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:

In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:

In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:

In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:

In a recent KPMG survey of deal-maker preference across healthcare and life sciences, late-stage assets garnered 70% of the vote, versus 55% for early-stage, highly innovative assets and 45% for agents at the commercial stage. Read more in Medical Marketing and Media:

#BioFuture2024 is where relentless therapeutic pioneers, innovators, and investors gather to assess and shape the future of therapeutics and digital health. Here's a glimpse into the important panel discussions, networking, and company presentations that you can experience. Register here to join us this Oct 28-30 >> https://bit.ly/3mF5BO4

#InflaRx CEO Niels Riedemann on the current funding environment for Biotech companies: ...Niels Riedemann, CEO and co-founder of #InflaRx N.V., also highlighted the positives. “The past year has taught us that, even in difficult times, good things can happen, and we did see some successful catalyst-triggered financings in 2023, including our own. We expect this to hold true for the year ahead. In addition, the pace of deal-making appears to be accelerating, with a steady stream of billion-dollar-plus collaborations and acquisitions making headlines.”... Scrip Asks...What Does 2024 Hold For Biopharma? Part 2: The Funding Environment, M&A And Partnering :: Scrip (citeline.com)

🌐 The Lynx.MD team is heading to San Diego for DIA 2024. Drug discovery is a complex, lengthy process. DIA brings together the life sciences community to discuss innovations accelerating advancements, bringing therapies to care faster. Reach out to the Lynx.MD team, including Collin Labar, on LinkedIn to learn more about how our partners are using Lynx.MD’s rich structured and unstructured data sets to find insights addressing medical affairs and market access. See you at #DIA2024! 🌟 #Data #Research

For my connections in Life Sciences, our next Going Global webinar is back. Register below to learn how you can grow your company internationally.